These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35812822)

  • 1. An overview of the BOIN design and its current extensions for novel early-phase oncology trials.
    Ananthakrishnan R; Lin R; He C; Chen Y; Li D; LaValley M
    Contemp Clin Trials Commun; 2022 Aug; 28():100943. PubMed ID: 35812822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials.
    Zhou Y; Lin R; Kuo YW; Lee JJ; Yuan Y
    JCO Clin Cancer Inform; 2021 Jan; 5():91-101. PubMed ID: 33439726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials.
    Yuan Y; Wu J; Gilbert MR
    Neurooncol Pract; 2021 Dec; 8(6):627-638. PubMed ID: 34777832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
    Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
    Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials.
    Zhou Y; Li R; Yan F; Lee JJ; Yuan Y
    Stat Biopharm Res; 2021; 13(2):147-155. PubMed ID: 34249223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
    Silva RB; Yap C; Carvajal R; Lee SM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
    Kakizume T; Takeda K; Taguri M; Morita S
    Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.
    Liu R; Yuan Y; Sen S; Yang X; Jiang Q; Li XN; Lu CC; Göneng M; Tian H; Zhou H; Lin R; Marchenko O
    Stat Biopharm Res; 2022; 14(3):270-282. PubMed ID: 37275462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early completion of phase I cancer clinical trials with Bayesian optimal interval design.
    Kojima M
    Stat Med; 2021 Jun; 40(14):3215-3226. PubMed ID: 33844323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
    Zhou H; Yuan Y; Nie L
    Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
    Kojima M
    BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs.
    Li C; Sun H; Cheng C; Tang L; Pan H
    Contemp Clin Trials Commun; 2022 Dec; 30():100990. PubMed ID: 36203850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should the choice of BOIN design parameter
    Lu R
    medRxiv; 2024 Mar; ():. PubMed ID: 38496500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of Bayesian optimal interval design by accounting for overdose and underdose errors trade-offs.
    Sadachi R; Sato H; Fujiwara T; Hirakawa A
    J Biopharm Stat; 2023 Nov; ():1-20. PubMed ID: 37966109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.